OBJECTIVE: Little is known about clinical features associated with the risk of recurrence in patients with bipolar disorder receiving treatment according to contemporary practice guidelines. The authors looked for the features associated with risk of recurrence. METHOD: The authors examined prospective data from a cohort of patients with bipolar disorder participating in the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study for up to 24 months. For those who were symptomatic at study entry but subsequently achieved recovery, time to recurrence of mania, hypomania, mixed state, or a depressive episode was examined with Cox regression. RESULTS: Of 1,469 participants symptomatic at study entry, 858 (58.4%) subsequently achieved recovery. During up to 2 years of follow-up, 416 (48.5%) of these individuals experienced recurrences, with more than twice as many developing depressive episodes (298, 34.7%) as those who developed manic, hypomanic, or mixed episodes (118, 13.8%). The time until 25% of the individuals experienced a depressive episode was 21.4 weeks and until 25% experienced a manic/hypomanic/mixed episode was 85.0 weeks. Residual depressive or manic symptoms at recovery and proportion of days depressed or anxious in the preceding year were significantly associated with shorter time to depressive recurrence. Residual manic symptoms at recovery and proportion of days of elevated mood in the preceding year were significantly associated with shorter time to manic, hypomanic, or mixed episode recurrence. CONCLUSIONS:Recurrence was frequent and associated with the presence of residual mood symptoms at initial recovery. Targeting residual symptoms in maintenance treatment may represent an opportunity to reduce risk of recurrence.
RCT Entities:
OBJECTIVE: Little is known about clinical features associated with the risk of recurrence in patients with bipolar disorder receiving treatment according to contemporary practice guidelines. The authors looked for the features associated with risk of recurrence. METHOD: The authors examined prospective data from a cohort of patients with bipolar disorder participating in the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study for up to 24 months. For those who were symptomatic at study entry but subsequently achieved recovery, time to recurrence of mania, hypomania, mixed state, or a depressive episode was examined with Cox regression. RESULTS: Of 1,469 participants symptomatic at study entry, 858 (58.4%) subsequently achieved recovery. During up to 2 years of follow-up, 416 (48.5%) of these individuals experienced recurrences, with more than twice as many developing depressive episodes (298, 34.7%) as those who developed manic, hypomanic, or mixed episodes (118, 13.8%). The time until 25% of the individuals experienced a depressive episode was 21.4 weeks and until 25% experienced a manic/hypomanic/mixed episode was 85.0 weeks. Residual depressive or manic symptoms at recovery and proportion of days depressed or anxious in the preceding year were significantly associated with shorter time to depressive recurrence. Residual manic symptoms at recovery and proportion of days of elevated mood in the preceding year were significantly associated with shorter time to manic, hypomanic, or mixed episode recurrence. CONCLUSIONS: Recurrence was frequent and associated with the presence of residual mood symptoms at initial recovery. Targeting residual symptoms in maintenance treatment may represent an opportunity to reduce risk of recurrence.
Authors: Thomas G Schulze; Martin Alda; Mazda Adli; Nirmala Akula; Raffaella Ardau; Elise T Bui; Caterina Chillotti; Sven Cichon; Piotr Czerski; Maria Del Zompo; Sevilla D Detera-Wadleigh; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Rebecca Hoban; Nakao Iwata; Layla Kassem; Tadafumi Kato; Sarah Kittel-Schneider; Sebastian Kliwicki; John R Kelsoe; Ichiro Kusumi; Gonzalo Laje; Susan G Leckband; Mirko Manchia; Glenda Macqueen; Takuya Masui; Norio Ozaki; Roy H Perlis; Andrea Pfennig; Paola Piccardi; Sara Richardson; Guy Rouleau; Andreas Reif; Janusz K Rybakowski; Johanna Sasse; Johannes Schumacher; Giovanni Severino; Jordan W Smoller; Alessio Squassina; Gustavo Turecki; L Trevor Young; Takeo Yoshikawa; Michael Bauer; Francis J McMahon Journal: Neuropsychobiology Date: 2010-05-08 Impact factor: 2.328
Authors: Thilo Deckersbach; Britta K Hölzel; Lori R Eisner; Jonathan P Stange; Andrew D Peckham; Darin D Dougherty; Scott L Rauch; Sara Lazar; Andrew A Nierenberg Journal: CNS Neurosci Ther Date: 2011-04-02 Impact factor: 5.243
Authors: David E Kemp; Stephen J Ganocy; Martin Brecher; Berit X Carlson; Suzanne Edwards; James M Eudicone; Gary Evoniuk; Wim Jansen; Andrew C Leon; Margaret Minkwitz; Andrei Pikalov; Hans H Stassen; Armin Szegedi; Mauricio Tohen; Arjen P P Van Willigenburg; Joseph R Calabrese Journal: J Affect Disord Date: 2010-11-10 Impact factor: 4.839
Authors: Michael J McCarthy; Heather Wei; Caroline M Nievergelt; Andrea Stautland; Adam X Maihofer; David K Welsh; Paul Shilling; Martin Alda; Ney Alliey-Rodriguez; Amit Anand; Ole A Andreasson; Yokesh Balaraman; Wade H Berrettini; Holli Bertram; Kristen J Brennand; Joseph R Calabrese; Cynthia V Calkin; Ana Claasen; Clara Conroy; William H Coryell; David W Craig; Nicole D'Arcangelo; Anna Demodena; Srdjan Djurovic; Scott Feeder; Carrie Fisher; Nicole Frazier; Mark A Frye; Fred H Gage; Keming Gao; Julie Garnham; Elliot S Gershon; Kara Glazer; Fernando Goes; Toyomi Goto; Gloria Harrington; Petter Jakobsen; Masoud Kamali; Elizabeth Karberg; Marisa Kelly; Susan G Leckband; Falk Lohoff; Melvin G McInnis; Francis Mondimore; Gunnar Morken; John I Nurnberger; Sarah Obral; Ketil J Oedegaard; Abigail Ortiz; Megan Ritchey; Kelly Ryan; Martha Schinagle; Helle Schoeyen; Candice Schwebel; Martha Shaw; Tatyana Shekhtman; Claire Slaney; Emma Stapp; Szabolcs Szelinger; Bruce Tarwater; Peter P Zandi; John R Kelsoe Journal: Neuropsychopharmacology Date: 2018-11-16 Impact factor: 7.853
Authors: Roy H Perlis; Jordan W Smoller; Manuel A R Ferreira; Andrew McQuillin; Nick Bass; Jacob Lawrence; Gary S Sachs; Vishwajit Nimgaonkar; Edward M Scolnick; Hugh Gurling; Pamela Sklar; Shaun Purcell Journal: Am J Psychiatry Date: 2009-05-15 Impact factor: 18.112